Abstract:Background: Human parvovirus B19 (B19) infection has been reported as a possible cause of autoimmune diseases. The association of B19 infection with adult-onset Still's diseases (AOSD) remains unclear. Methods: IgM and IgG against B19-VP1/2 were determined using ELISA in 86 patients with AOSD, 58 patients with systemic lupus erythematosus (SLE) and 64 healthy controls. Anti-B19-VP1-unique region (VP1u) and anti-B19-nonstructural protein-1(NS1) antibodies were assessed by Western blot. B19 DNA was detected by nested PCR. Results: Forty-three (50.0%) of 86 AOSD patients, 27 (46.6%) of 58 SLE patients and 30 (46.9%) of 64 controls had positivity for anti-B19-VP1/2-IgG in the absence of anti-B19-VP1/2-IgM, indicating past infection. None of enrolled subjects had detectable circulating B19 DNA. Significantly higher positivity rates for anti-B19-VP1u and anti-B19-NS1 IgG were observed in AOSD patients (39.5% and 46.5% respectively) and SLE patients (34.5% and 36.2% respectively) than in healthy controls (14.1%, p<0.005 for AOSD and p<0.05 for SLE, and 15.6%, p<0.001 for AOSD and p<0.05 for SLE; respectively). AOSD patients and SLE patients with seropositive results for anti-B19-VP1/2 IgG, anti-B19-VP1u or anti-B19-NS1 antibodies had a higher frequency of leucopenia and thrombocytopenia when compared to those with seronegative results. AOSD patients with anti-B19-VP1u or anti-B19-NS1 antibodies were more likely to have arthritis in comparison with those without these antibodies. Conclusions: Higher seroreactivity for anti-B19-VP1u and anti-B19-NS1 IgG were associated with cytopenia in both AOSD and SLE patients with unique correlation to arthritis in the AOSD. Further studies are necessary to determine if these responses correlate with a common genetic risk in patients with AOSD and SLE.

[Review of correlation between human parvovirus B19 and autoimmune disease etiology]

Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses

The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease

Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

Parvovirus B19 and immune disorders

Significant association of past parvovirus B19 infection with cytopenia in both adult-onset Still's disease and systemic lupus erythematosus patients

Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway?

Parvovirus B19 in Rheumatic Diseases

[Parvovirus B19 infections in adults]

Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis

Th17-related cytokines in systemic lupus erythematosus patients with dilated cardiomyopathies: a possible linkage to parvovirus B19 infection

Parvovirus B19 Infection Associated with Hashimoto's Thyroiditis in Adults

The Relation Between the Parvovirus B19 and Pregnancy

Infectious arthritis caused by human parvovirus B19: case report and literature review

Does parvovirus infection have a role in systemic lupus erythematosus?

Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy

A review of blood diseases and cytopenias associated with human parvovirus B19 infection

Neurological aspects of human parvovirus B19 infection: a systematic review

A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection

Effect of the Functional VP1 Unique Region of Human Parvovirus B19 in Causing Skin Fibrosis of Systemic Sclerosis

Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein